MEDtalks: Interpretation of Urine Drug Screens; Cervical Cancer Screening & Prevention Recorded Session

Interpretation of Urine Drug Screens:
Urine drug testing is just one of many valuable tools for assessing unexplained toxic symptoms, monitoring adherence, treating patients with addiction, and prescribing controlled substances. An appropriate understanding of the limitations of the methods employed helps to minimize misinterpretation and provides a clearer understanding of the results. Clinicians need to understand the causes of unexpected results as it relates to false positive and false negative results and assay performance characteristics.

Cervical Cancer Screening & Prevention:
Longitudinal studies have shown that in patients with untreated in situ cervical cancer, 30% to 70% will develop invasive carcinoma over a period of 10 to 12 years. However, in about 10% of patients, lesions can progress from in situ to invasive in a period of less than 1 year. This lecture addresses how to identify and prevent cervical cancer.

If you attended the live session of  Interpretation of Urine Drug Screens; Cervical Cancer Screening & Prevention,  you will not be able to claim credit again.  You can however, still watch the content.

Target Audience

This course is intended for all AAH team members with focus on patient and provider well-being most relevant to clinical staff (physicians, advanced practice providers, and nurses)

Learning Objectives

Interpretation of Urine Drug Screens:
At the completion of this activity, the participant should be able to:

  • Describe the value that urine drug testing provides in overall patient management.
  • Understand the limitations of the methodology used for urine drug testing.
  • Understand the possible causes of unexpected results from urine drug testing
  • Cervical Cancer Screening & Prevention:

Cervical Cancer Screening & Prevention:
At the completion of this activity, the participant should be able to:

  • Understand the history and epidemiology of cervical cancer
  • Consider risk factors and risk reduction strategies
  • Determine the appropriateness and timing of specialty referral
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
    Attendance Credit
    • 1.00 Approved AMA PRA Category 1 Credit™
Course opens: 
10/08/2020
Course expires: 
12/31/2022
Cost:
$0.00
Rating: 
0

Faculty

Planners:
Diana Bottari, DO, Lead Physician MEDtalks & Opioid Mitigation Strategies, Advocate Aurora Health
Chintan Mistry, MD, Advocate Aurora Health
Kevin McCune, MD, Advocate Aurora Health

Speakers:
Interpretation of Urine Drug Screens: Ken Copeland, PhD, DABCC - Technical Director, Chemistry, ACL Laboratories
Cervical Cancer Screening & Prevention: Dakisha Lewis, MD - Physician – OB/GYN, Advocate Aurora Health

 

Disclosure

The planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose.

Accreditation Statement
Advocate Aurora Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Advocate Aurora Health designates this enduring material for a maximum of 1.00 AMA PRA Category 1 credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
  • 1.00 Attendance
    Attendance Credit
    • 1.00 Approved AMA PRA Category 1 Credit™

Price

Cost:
$0.00
Please login or register to take this course.

If you attended the live session of  Interpretation of Urine Drug Screens; Cervical Cancer Screening & Prevention,  you will not be able to claim credit again.  You can however, still watch the content.

Click “Take Course” to register for this program.  

If you have questions, please contact Advocate Aurora Continuing Medical Education Office at cme@aah.org

Main sessions